company background image
MAH0 logo

Mereo BioPharma Group BST:MAH0 Stock Report

Last Price

€3.62

Market Cap

€497.3m

7D

0%

1Y

n/a

Updated

23 Dec, 2024

Data

Company Financials +

Mereo BioPharma Group plc

BST:MAH0 Stock Report

Market Cap: €497.3m

MAH0 Stock Overview

A biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. More details

MAH0 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Mereo BioPharma Group plc Competitors

Price History & Performance

Summary of share price highs, lows and changes for Mereo BioPharma Group
Historical stock prices
Current Share PriceUS$3.62
52 Week HighUS$4.56
52 Week LowUS$1.98
Beta0.91
1 Month Change-2.95%
3 Month Change-4.74%
1 Year Changen/a
3 Year Change164.23%
5 Year Change212.07%
Change since IPO-26.19%

Recent News & Updates

Recent updates

Shareholder Returns

MAH0DE BiotechsDE Market
7D0%-3.5%-2.0%
1Yn/a-14.7%6.9%

Return vs Industry: Insufficient data to determine how MAH0 performed against the German Biotechs industry.

Return vs Market: Insufficient data to determine how MAH0 performed against the German Market.

Price Volatility

Is MAH0's price volatile compared to industry and market?
MAH0 volatility
MAH0 Average Weekly Movementn/a
Biotechs Industry Average Movement6.8%
Market Average Movement4.9%
10% most volatile stocks in DE Market11.3%
10% least volatile stocks in DE Market2.4%

Stable Share Price: MAH0's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: Insufficient data to determine MAH0's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
201533Denise Scots-Knightwww.mereobiopharma.com

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials.

Mereo BioPharma Group plc Fundamentals Summary

How do Mereo BioPharma Group's earnings and revenue compare to its market cap?
MAH0 fundamental statistics
Market cap€497.32m
Earnings (TTM)-€43.43m
Revenue (TTM)€958.40k

518.9x

P/S Ratio

-11.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
MAH0 income statement (TTM)
RevenueUS$1.00m
Cost of Revenue-US$273.00k
Gross ProfitUS$1.27m
Other ExpensesUS$46.59m
Earnings-US$45.32m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.29
Gross Margin127.30%
Net Profit Margin-4,531.60%
Debt/Equity Ratio7.7%

How did MAH0 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 06:31
End of Day Share Price 2024/12/09 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Mereo BioPharma Group plc is covered by 9 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jack AllenBaird
Yun ZhongBTIG
Julian HarrisonBTIG